Pathogen Genomes as Global Public Goods (and Why They Should Not Be Patented) (preprint)

During past viral outbreaks, researchers rushed to patent genomic sequences of the viruses as they were discovered, leading to disputes and delays in research coordination. Yet similar disputes did not occur with respect to the genomic sequence of SARS-CoV-2, the virus responsible for COVID-19. With respect to COVID-19, global research collaboration occurred rapidly, leading to the identification of new variants, the ability to track the spread of the disease, and the development of vaccines and therapeutics in record time. The lack of patenting of SARS-CoV-2 is likely due the U.S. Supreme Court’s 2013 ruling in Association for Molecular Pathology v. Myriad Genetics, which established that naturally occurring genomic sequences are ineligible for patent protection, a decision that has had repercussions around the world. Recently, however, legislative proposals have been made in the U.S. to overturn this decision. Such legislation, if enacted, would enable researchers, likely based in countries where pathogenic outbreaks first occur, to obtain U.S. patents on pathogen genomes. Given that ample opportunities exist for patenting of diagnostics, vaccines, therapeutics and other downstream innovations, steps should be taken at national and international levels to ensure that pathogenic sequence data cannot be appropriated by individual researchers, institutions, or states.

Greater Traditionalism Predicts COVID-19 Precautionary Behaviors Across 27 Societies (preprint)

People vary in the extent to which they embrace their society’s traditions, impacting a range of social and political phenomena. People also vary in the degree to which they perceive disparate dangers as salient and necessitating a response. Over evolutionary time, traditions likely regularly offered direct and indirect avenues for addressing hazards; consequently, via multiple possible pathways, orientations toward tradition and toward danger may have become associated. Emerging research documents connections between individual differences in traditionalism and variation in threat responsivity in general, and pathogen-avoidance motivations in particular. Importantly, because threat-mitigating behaviors can conflict with competing priorities, the precise associations between traditionalism and pathogen avoidance likely depend on contextually contingent costs and benefits. The COVID-19 pandemic requires individuals to make decisions about consequential and costly pathogen-avoidance behaviors that can clash with other priorities. The pandemic therefore provides a real-world setting in which to test the posited relationship between traditionalism and pathogen avoidance across socio-political contexts. Across 27 societies (N = 7,844), we find that costly COVID-19-avoidance behaviors positively correlate with greater endorsement of traditional norms and values in a majority of countries. Accounting for the conflict that arises in some societies between public health precautions and competing priorities, such as the exercise of personal liberties, reveals a consistent relationship between traditionalism and COVID-19 precautions across an even wider range of social and cultural contexts. These findings support the thesis that traditionalism is associated with an enhanced tendency to attend to hazards.

Immunogenicity of COVID-19 mRNA Vaccines in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome (preprint)

Immunocompromised patients are particularly susceptible to serious complications from infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Two mRNA vaccines, BNT162b2 and mRNA-1273, have been shown to have excellent clinical efficacy in immunocompetent adults, but diminished activity in immunocompromised patients. In this study, we measured anti-spike SARS-CoV-2 antibody response, avidity, and surrogate neutralizing antibody activity in Coronavirus Disease 2019 (COVID-19) vaccinated patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Anti-spike SARS-CoV-2 antibody was present in 89% of AML and 88% of MDS patients, but median antibody levels for were lower than in healthy controls (p=0.001 and p=0.04, respectively). SARS-CoV-2 antibody avidity and neutralizing antibody activity from AML patients were significantly lower than controls (p=0.028 and p=0.002, respectively). There was a trend toward higher anti-spike SARS-CoV-2 antibody levels after mRNA-1273 vaccination. Antibody avidity was greater in patients after mRNA-1273 versus BNT162b2 (p=0.01) and there was a trend toward greater neutralizing antibody activity after mRNA-1273 versus BNT162b2 vaccination.

Pledging Intellectual Property for COVID-19 (preprint)

COVID-19 differs from other recent public health crises with respect to its sudden onset, its rapid spread, the lack of any known vaccine or cure and resulting shortages of critical medical equipment. The convergence of these factors has prompted both governments and IPR holders around the world to seek ways to increase the availability of IPR necessary to combat the pandemic. Governmental compulsory licensing, IPR pools and voluntary IPR pledges have all been used in the past, though in situations that differ in important respects from the COVID-19 pandemic. Each is designed to result, to a greater or lesser degree, in a publicly-accessible “commons” of rights and technologies that are broadly available for use to support an important public health goals. Here, we compare and contrast these differing approaches to IPR commons formation and assess their suitability to address the COVID-19 crisis.